Search research articles
Contact Us
Filters
Showing results (31-40 of 67) with videos related to
Page
of 7
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
November 19, 2018
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
Chen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
Plos One
|
September 15, 2015
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients
Chi-Chieh Yang, Wei-Lun Tsai, Wei-Wen Su, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology
|
November 21, 2022
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C
Chi-Yi Chen, Wan-Long Chuang, Albert Qin, et al.
The Lancet. Gastroenterology & Hepatology
|
February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
Clinical and Molecular Hepatology
|
July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Gut
|
January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International
|
March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International
|
January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C
Yen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 67) with videos related to
Sort By:
Page
of 7
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
November 19, 2018
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
Chen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
Plos One
|
September 15, 2015
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients
Chi-Chieh Yang, Wei-Lun Tsai, Wei-Wen Su, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology
|
November 21, 2022
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C
Chi-Yi Chen, Wan-Long Chuang, Albert Qin, et al.
The Lancet. Gastroenterology & Hepatology
|
February 6, 2025
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial
Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, et al.
Clinical and Molecular Hepatology
|
July 13, 2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Gut
|
January 7, 2021
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, et al.
Hepatology International
|
March 7, 2021
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, et al.
Hepatology International
|
January 26, 2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C
Yen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Page
of 7